Brokerages Set Evolus Inc (NASDAQ:EOLS) PT at $26.33

Shares of Evolus Inc (NASDAQ:EOLS) have been given an average rating of “Buy” by the twelve brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $26.33.

Several equities research analysts recently commented on the company. Leerink Swann assumed coverage on Evolus in a research report on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective on the stock. Svb Leerink initiated coverage on Evolus in a research note on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective on the stock. JMP Securities dropped their target price on Evolus from $35.00 to $30.00 and set a “market outperform” rating for the company in a report on Tuesday, August 13th. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating on shares of Evolus in a research note on Tuesday, November 5th. Finally, Mizuho reiterated a “buy” rating and set a $30.00 price target on shares of Evolus in a report on Thursday, September 5th.

EOLS stock traded down $0.01 during mid-day trading on Tuesday, reaching $12.50. The company’s stock had a trading volume of 6,537 shares, compared to its average volume of 758,462. The company has a current ratio of 3.66, a quick ratio of 3.28 and a debt-to-equity ratio of 4.53. The company’s 50 day moving average is $14.85 and its two-hundred day moving average is $15.51. Evolus has a fifty-two week low of $10.22 and a fifty-two week high of $30.25. The stock has a market cap of $417.98 million, a PE ratio of -7.97 and a beta of 4.44.

Evolus (NASDAQ:EOLS) last issued its earnings results on Monday, November 4th. The company reported ($0.78) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.33) by $0.55. The company had revenue of $13.17 million for the quarter, compared to analyst estimates of $5.18 million. On average, analysts forecast that Evolus will post -3.75 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. Ladenburg Thalmann Financial Services Inc. grew its position in Evolus by 2,224.0% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock worth $34,000 after acquiring an additional 2,224 shares during the period. Prime Capital Investment Advisors LLC purchased a new stake in Evolus in the second quarter valued at $44,000. Royal Bank of Canada lifted its stake in shares of Evolus by 429.1% in the 2nd quarter. Royal Bank of Canada now owns 4,365 shares of the company’s stock valued at $64,000 after purchasing an additional 3,540 shares during the last quarter. Metropolitan Life Insurance Co NY acquired a new position in shares of Evolus in the 1st quarter valued at $83,000. Finally, UBS Asset Management Americas Inc. purchased a new position in shares of Evolus during the 2nd quarter worth $156,000. Hedge funds and other institutional investors own 16.94% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Further Reading: Do You Need a Fiduciary?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.